Blogger
WonderDrug
My Photo

View Full Size

On Blogger since: August 2011
Profile views: 856
Report Abuse

My blogs

2014 PBAC submissions and outcomes – winners and losers
PBAC agenda - November 2013
Is it getting harder to secure a recommendation for submissions that include a CEA?
PBAC agenda - July 2012
PBAC outcomes - March 2013 meeting
2014 PBAC submissions and outcomes – therapeutic areas
PBAC submissions and outcomes – 2014 in review
2014 in review – new medicines listed in the New Zealand Pharmaceutical Schedule
COMPARE report - a missed opportunity?
Reimbursement of new medicines in Australia and New Zealand in 2012
2014 in review - IQWiG
PBAC outcomes - November 2014 meeting
PBAC outcomes - March 2012 meeting
PBAC 2012 submissions and outcomes for new medicines – international comparison
2012 PBAC submissions and recommendations for orphan drugs – an equitable year?
PBAC outcomes - July 2013 meeting
Submissions to the PBAC – is it getting harder to secure a recommendation?
PBAC outcomes - November 2012 meeting
The success rate for CMA submissions to the PBAC is falling
Risk sharing arrangements – when does an optional extra become a standard accessory?
2012 PBAC submissions and outcomes - winners and losers
PBAC agenda - March 2012
NICE and PBAC reach different conclusions about Gilenya (fingolimod) for MS
PBAC agenda - March 2013
PBAC agenda - March 2015
PBAC agenda - July 2014
2014 in review – new medicines listed on the PBS
PBAC outcomes - March 2014 meeting
2014 in review – NICE
2014 in review – CADTH
PBAC agenda - November 2012
Access to new cancer drugs in US and Australia
2014 in review – SMC
PBAC agenda - July 2015
2012 PBAC submissions and recommendations by WHO ATC main group; harder for some?
PBAC outcomes - July 2012 meeting
PBAC meeting - July 2011
PBAC meeting - November 2011
PBAC submissions and outcomes - 2012 in review

About me

IndustryBusiness Services
OccupationMarket access consultant
LocationSydney, NSW, Australia
Google apps
Main menu